Ironwood Pharmaceuticals, Inc. – NASDAQ:IRWD
Ironwood Pharmaceuticals stock price today
$1.099
-3.35
-75.3%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
Ironwood Pharmaceuticals stock price monthly change
-31.33%
month
Ironwood Pharmaceuticals stock price quarterly change
-31.33%
quarter
Ironwood Pharmaceuticals stock price yearly change
-61.34%
year
Ironwood Pharmaceuticals key metrics
Market Cap | 695.32M |
Enterprise value | 1.42B |
P/E | 10.88 |
EV/Sales | 3.46 |
EV/EBITDA | 5.44 |
Price/Sales | 4.04 |
Price/Book | 2.54 |
PEG ratio | -0.16 |
EPS | -6.77 |
Revenue | 413.55M |
EBITDA | -958.02M |
Income | -1.05B |
Revenue Q/Q | -28.04% |
Revenue Y/Y | -0.85% |
Profit margin | 42.64% |
Oper. margin | 60.97% |
Gross margin | 47.43% |
EBIT margin | 60.97% |
EBITDA margin | -231.66% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIronwood Pharmaceuticals stock price history
Ironwood Pharmaceuticals stock forecast
Ironwood Pharmaceuticals financial statements
| Jun 2023 | 107.38M | -1.06B | -989.17% |
|---|---|---|---|
| Sep 2023 | 113.73M | 15.32M | 13.47% |
| Dec 2023 | 117.55M | -1.08M | -0.92% |
| Mar 2024 | 74.87M | -4.16M | -5.56% |
| Mar 2024 | 74.87M | -4.16M | -5.56% |
|---|---|---|---|
| Sep 2025 | 127.05M | 34.32M | 27.02% |
| Oct 2025 | 120.6M | 32.32M | 26.81% |
| Dec 2025 | 136.55M | 40.21M | 29.45% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 603220000 | 949.99M | 157.49% |
|---|---|---|---|
| Sep 2023 | 524063000 | 849.74M | 162.15% |
| Dec 2023 | 471073000 | 817.36M | 173.51% |
| Mar 2024 | 438819000 | 769.33M | 175.32% |
| Jun 2023 | 34.96M | -999.49M | 399.07M |
|---|---|---|---|
| Sep 2023 | 32.45M | -22.62M | -74.98M |
| Dec 2023 | 35.83M | -4.18M | -50.90M |
| Mar 2024 | 44.98M | -68K | -15.55M |
Ironwood Pharmaceuticals alternative data
| Aug 2023 | 219 |
|---|---|
| Sep 2023 | 219 |
| Oct 2023 | 219 |
| Nov 2023 | 219 |
| Dec 2023 | 219 |
| Jan 2024 | 219 |
| Feb 2024 | 219 |
| Mar 2024 | 267 |
| Apr 2024 | 267 |
| May 2024 | 267 |
| Jun 2024 | 267 |
| Jul 2024 | 267 |
Ironwood Pharmaceuticals other data
91.70%
-7.77%
of IRWD is owned by hedge funds
233
+21
173.80M
+10.26M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 9926 |
| Feb 2024 | 0 | 280916 |
| Mar 2024 | 17604 | 0 |
| May 2024 | 0 | 123875 |
| Jun 2024 | 0 | 102766 |
| Aug 2024 | 0 | 13017 |
| Nov 2024 | 0 | 16361 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DAVIS ANDREW officer: SVP, Chief Business Of.. | Class A Common Stock | 5,360 | $4.08 | $21,869 | ||
Sale | EMANY SRAVAN KUMAR officer: SVP, COO and CFO | Class A Common Stock | 11,001 | $4.08 | $44,884 | ||
Sale | JOHN MINARDO officer: Chief Legal Officer | Class A Common Stock | 9,910 | $4.27 | $42,316 | ||
Sale | SILVER RONALD officer: Principal Accounting O.. | Class A Common Stock | 3,107 | $4.27 | $13,267 | ||
Sale | MCHUGH JULIE director | Class A Common Stock | 22,766 | $6.29 | $143,198 | ||
Sale | MOUKHEIBIR CATHERINE director | Class A Common Stock | 35,574 | $6.61 | $235,144 | ||
Sale | MOUKHEIBIR CATHERINE director | Class A Common Stock | 44,426 | $6.36 | $282,549 | ||
Sale | SHETZLINE MICHAEL officer: CMO,SVP,.. | Class A Common Stock | 16,128 | $6.45 | $104,026 | ||
Sale | JOHN MINARDO officer: Chief Legal Officer | Class A Common Stock | 17,404 | $6.45 | $112,256 | ||
Sale | MCCOURT THOMAS A director, officer.. | Class A Common Stock | 67,618 | $6.45 | $436,136 |
| Patent |
|---|
Application Filling date: 14 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 11 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 13 Jan 2022 Issue date: 5 May 2022 |
Application Filling date: 7 Jan 2022 Issue date: 28 Apr 2022 |
Application Filling date: 30 Dec 2021 Issue date: 21 Apr 2022 |
Application Filling date: 20 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 20 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 18 Oct 2021 Issue date: 3 Feb 2022 |
Application Filling date: 27 Aug 2021 Issue date: 16 Dec 2021 |
Application Filling date: 2 Jun 2021 Issue date: 23 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Ironwood Pharmaceuticals: The Right Play Now
Ironwood: Pipeline Progresses As FDA Approves LINZESS
Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Ardelyx: Speculative Biotech With Minimal Downside Risk For Time Being
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Ironwood Pharmaceuticals: Undervalued Company With Steady Growth
The Stocks To Focus On Today
-
What's the price of Ironwood Pharmaceuticals stock today?
One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $1.1.
-
When is Ironwood Pharmaceuticals's next earnings date?
Unfortunately, Ironwood Pharmaceuticals's (IRWD) next earnings date is currently unknown.
-
Does Ironwood Pharmaceuticals pay dividends?
No, Ironwood Pharmaceuticals does not pay dividends.
-
How much money does Ironwood Pharmaceuticals make?
Ironwood Pharmaceuticals has a market capitalization of 695.32M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.83% to 442.74M US dollars.
-
What is Ironwood Pharmaceuticals's stock symbol?
Ironwood Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "IRWD".
-
What is Ironwood Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Ironwood Pharmaceuticals?
Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ironwood Pharmaceuticals's key executives?
Ironwood Pharmaceuticals's management team includes the following people:
- Mr. Thomas A. McCourt Chief Executive Officer & Director(age: 68, pay: $944,570)
- Mr. Jason Rickard Chief Operating Officer & Senior Vice President of Operations(age: 54, pay: $940,060)
- Dr. Michael Shetzline M.D., Ph.D. Chief Medical Officer, Senior Vice President and Head of R&D(age: 66, pay: $770,280)
- Ms. Julie H. McHugh Executive Chairman(age: 61, pay: $95,000)
-
How many employees does Ironwood Pharmaceuticals have?
As Jul 2024, Ironwood Pharmaceuticals employs 267 workers.
-
When Ironwood Pharmaceuticals went public?
Ironwood Pharmaceuticals, Inc. is publicly traded company for more then 15 years since IPO on 3 Feb 2010.
-
What is Ironwood Pharmaceuticals's official website?
The official website for Ironwood Pharmaceuticals is ironwoodpharma.com.
-
Where are Ironwood Pharmaceuticals's headquarters?
Ironwood Pharmaceuticals is headquartered at 100 Summer Street, Boston, MA.
-
How can i contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals's mailing address is 100 Summer Street, Boston, MA and company can be reached via phone at +61 76217722.
Ironwood Pharmaceuticals company profile:
Ironwood Pharmaceuticals, Inc.
ironwoodpharma.comExchange:
NASDAQ
Full time employees:
267
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
100 Summer Street
Boston, MA 02110
Boston, MA 02110
CIK: 0001446847
ISIN: US46333X1081
CUSIP: 46333X108
